Strategies to improve the stability of amorphous solid dispersions in view of the hot melt extrusion (HME) method
Copyright © 2023 Elsevier B.V. All rights reserved..
Oral administration of drugs is preferred over other routes for several reasons: it is non-invasive, easy to administer, and easy to store. However, drug formulation for oral administration is often hindered by the drug's poor solubility, which limits its bioavailability and reduces its commercial value. As a solution, amorphous solid dispersion (ASD) was introduced as a drug formulation method that improves drug solubility by changing the molecular structure of the drugs from crystalline to amorphous. The hot melt extrusion (HME) method is emerging in the pharmaceutical industry as an alternative to manufacture ASD. However, despite solving solubility issues, ASD also exposes the drug to a high risk of crystallisation, either during processing or storage. Formulating a successful oral administration drug using ASD requires optimisation of the formulation, polymers, and HME manufacturing processes applied. This review presents some important considerations in ASD formulation, including strategies to improve the stability of the final product using HME to allow more new drugs to be formulated using this method.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:647 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 647(2023) vom: 25. Nov., Seite 123536 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al-Japairai, Khater [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 27.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2023.123536 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363574581 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363574581 | ||
| 003 | DE-627 | ||
| 005 | 20231226093633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2023.123536 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363574581 | ||
| 035 | |a (NLM)37865133 | ||
| 035 | |a (PII)S0378-5173(23)00957-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al-Japairai, Khater |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Strategies to improve the stability of amorphous solid dispersions in view of the hot melt extrusion (HME) method |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Oral administration of drugs is preferred over other routes for several reasons: it is non-invasive, easy to administer, and easy to store. However, drug formulation for oral administration is often hindered by the drug's poor solubility, which limits its bioavailability and reduces its commercial value. As a solution, amorphous solid dispersion (ASD) was introduced as a drug formulation method that improves drug solubility by changing the molecular structure of the drugs from crystalline to amorphous. The hot melt extrusion (HME) method is emerging in the pharmaceutical industry as an alternative to manufacture ASD. However, despite solving solubility issues, ASD also exposes the drug to a high risk of crystallisation, either during processing or storage. Formulating a successful oral administration drug using ASD requires optimisation of the formulation, polymers, and HME manufacturing processes applied. This review presents some important considerations in ASD formulation, including strategies to improve the stability of the final product using HME to allow more new drugs to be formulated using this method | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Drug | |
| 650 | 4 | |a Hot melt extrusion | |
| 650 | 4 | |a Polymer | |
| 650 | 4 | |a Solid dispersion | |
| 650 | 4 | |a Stability | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Hamed Almurisi, Samah |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmood, Syed |e verfasserin |4 aut | |
| 700 | 1 | |a Madheswaran, Thiagarajan |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Bappaditya |e verfasserin |4 aut | |
| 700 | 1 | |a Sri, Prasanthi |e verfasserin |4 aut | |
| 700 | 1 | |a Azra Binti Ahmad Mazlan, Nadiatul |e verfasserin |4 aut | |
| 700 | 1 | |a Al Hagbani, Turki |e verfasserin |4 aut | |
| 700 | 1 | |a Alheibshy, Fawaz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 647(2023) vom: 25. Nov., Seite 123536 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:647 |g year:2023 |g day:25 |g month:11 |g pages:123536 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2023.123536 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 647 |j 2023 |b 25 |c 11 |h 123536 | ||